1
|
Iriarte A, Ochoa-Callejero L, García-Sanmartín J, Cerdà P, Garrido P, Narro-Íñiguez J, Mora-Luján JM, Jucglà A, Sánchez-Corral MA, Cruellas F, Gamundi E, Ribas J, Castellote J, Viñals F, Martínez A, Riera-Mestre A. Adrenomedullin as a potential biomarker involved in patients with hereditary hemorrhagic telangiectasia. Eur J Intern Med 2021; 88:89-95. [PMID: 33888392 DOI: 10.1016/j.ejim.2021.03.039] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Revised: 03/28/2021] [Accepted: 03/30/2021] [Indexed: 12/12/2022]
Abstract
BACKGROUND Adrenomedullin (AM) is a vasoactive peptide mostly secreted by endothelial cells with an important role in preserving endothelial integrity. The relationship between AM and hereditary hemorrhagic telangiectasia (HHT) is unknown. We aimed to compare the serum levels and tissue expression of AM between HHT patients and controls. METHODS Serum AM levels were measured by radioimmunoassay and compared between control and HHT groups. AM levels were also compared among HHT subgroups according to clinical characteristics. The single nucleotide polymorphism (SNP) rs4910118 was assessed by restriction analysis and sequencing. AM immunohistochemistry was performed on biopsies of cutaneous telangiectasia from eight HHT patients and on the healthy skin from five patients in the control group. RESULTS Forty-five HHT patients and 50 healthy controls were included, mean age (SD) was 50.7 (14.9) years and 46.4 (9.9) years (p = 0.102), respectively. HHT patients were mostly female (60% vs 38%, p = 0.032). Median [Q1-Q3] serum AM levels were 68.3 [58.1-80.6] pg/mL in the HHT group and 47.7 [43.2-53.8] pg/mL in controls (p<0.001), with an optimal AM cut-off according to Youden's J statistic of 55.32 pg/mL (J:0.729). Serum AM levels were similar in the HHT subgroups. No patient with HHT had the SNP rs4910118. AM immunoreactivity was found with high intensity in the abnormal blood vessels of HHT biopsies. CONCLUSIONS We detected higher AM serum levels and tissue expression in patients with HHT than in healthy controls. The role of AM in HHT, and whether AM may constitute a novel biomarker and therapeutic target, needs further investigation.
Collapse
Affiliation(s)
- A Iriarte
- HHT Unit. Hospital Universitari de Bellvitge, Barcelona Spain; Internal Medicine Department. Hospital Universitari de Bellvitge, Barcelona Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona Spain
| | - L Ochoa-Callejero
- Angiogenesis Group, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño Spain
| | - J García-Sanmartín
- Angiogenesis Group, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño Spain
| | - P Cerdà
- HHT Unit. Hospital Universitari de Bellvitge, Barcelona Spain; Internal Medicine Department. Hospital Universitari de Bellvitge, Barcelona Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona Spain
| | - P Garrido
- Angiogenesis Group, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño Spain
| | - J Narro-Íñiguez
- Angiogenesis Group, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño Spain
| | - J M Mora-Luján
- HHT Unit. Hospital Universitari de Bellvitge, Barcelona Spain; Internal Medicine Department. Hospital Universitari de Bellvitge, Barcelona Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona Spain
| | - A Jucglà
- HHT Unit. Hospital Universitari de Bellvitge, Barcelona Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona Spain; Dermatology Department. Hospital Universitari de Bellvitge, Barcelona Spain
| | - M A Sánchez-Corral
- HHT Unit. Hospital Universitari de Bellvitge, Barcelona Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona Spain; Cardiology Department. Hospital Universitari de Bellvitge, Barcelona Spain
| | - F Cruellas
- HHT Unit. Hospital Universitari de Bellvitge, Barcelona Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona Spain; Otorhinolaryngology Department. Hospital Universitari de Bellvitge, Barcelona Spain
| | - E Gamundi
- Hematology Department. Hospital Universitari de Bellvitge, Barcelona Spain
| | - J Ribas
- HHT Unit. Hospital Universitari de Bellvitge, Barcelona Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona Spain; Pneumology Department. Hospital Universitari de Bellvitge, Barcelona Spain
| | - J Castellote
- HHT Unit. Hospital Universitari de Bellvitge, Barcelona Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona Spain; Liver Transplant Unit, Gastroenterology Department. Hospital Universitari de Bellvitge, Barcelona Spain; Physiological Sciences Department. Faculty of Medicine and Health Sciences. Universitat de Barcelona, Barcelona, Spain
| | - F Viñals
- Physiological Sciences Department. Faculty of Medicine and Health Sciences. Universitat de Barcelona, Barcelona, Spain; Program Against Cancer Therapeutic Resistance, Institut Catala d'Oncologia, Hospital Duran i Reynals, Barcelona Spain; Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - A Martínez
- Angiogenesis Group, Oncology Area, Center for Biomedical Research of La Rioja (CIBIR), Logroño Spain
| | - A Riera-Mestre
- HHT Unit. Hospital Universitari de Bellvitge, Barcelona Spain; Internal Medicine Department. Hospital Universitari de Bellvitge, Barcelona Spain; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona Spain; Faculty of Medicine and Health Sciences. Universitat de Barcelona, Barcelona, Spain.
| |
Collapse
|
2
|
Mora-Luján JM, Iriarte A, Alba E, Sánchez-Corral MA, Cerdà P, Cruellas F, Ordi Q, Corbella X, Ribas J, Castellote J, Riera-Mestre A. Gender differences in hereditary hemorrhagic telangiectasia severity. Orphanet J Rare Dis 2020; 15:63. [PMID: 32122373 PMCID: PMC7053104 DOI: 10.1186/s13023-020-1337-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 02/25/2020] [Indexed: 12/13/2022] Open
Abstract
Background Gender differences in organ involvement and clinical severity have been poorly described in hereditary hemorrhagic telangiectasia (HHT). The aim of this study was to describe differences in the severity of HHT manifestations according to gender. Methods Severity was measured according to Epistaxis Severity Score (ESS), Simple Clinical Scoring Index for hepatic involvement, a general HHT-score, needing for invasive treatment (pulmonary or brain arteriovenous malformations -AVMs- embolization, liver transplantation or Young’s surgery) or the presence of adverse outcomes (severe anemia, emergency department -ED- or hospital admissions and mortality). Results One hundred forty-two (58.7%) women and 100 (41.3%) men were included with a mean age of 48.9 ± 16.6 and 49 ± 16.5 years, respectively. Women presented hepatic manifestations (7.1% vs 0%) and hepatic involvement (59.8% vs 47%), hepatic AVMs (28.2% vs 13%) and bile duct dilatation (4.9% vs 0%) at abdominal CT, and pulmonary AVMs at thoracic CT (35.2% vs 23%) more often than men. The Simple Clinical Scoring Index was higher in women (3.38 ± 1.2 vs 2.03 ± 1.2), and more men were considered at low risk of harboring clinically significant liver disease than women (61% vs 25.3%). These differences were mantained when considering HHT1 and HHT2 patients separetely. Duodenal telangiectasia were more frequent in men than women (21% vs 9.8%). Invasive treatments were more frequently needed in women (28.2% vs 16%) but men needed attention at the ED more often than women (48% vs 28.2%), with no differences in ESS, HHT-score, anemia hospital admissions or mortality. Conclusions HHT women showed more severe hepatic involvement than men, also among HHT1 and HHT2 patients. Women had higher prevalence of pulmonary AVMs and needed invasive procedures more frequently, while men needed attention at the ED more often. These data might help physicians to individualize HHT patients follow-up.
Collapse
Affiliation(s)
- J M Mora-Luján
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Internal Medicine Department, Hospital Universitari Bellvitge, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - A Iriarte
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Internal Medicine Department, Hospital Universitari Bellvitge, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - E Alba
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.,Radiology Department, Hospital Universitari Bellvitge, Barcelona, Spain
| | - M A Sánchez-Corral
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.,Cardiology Department, Hospital Universitari Bellvitge, Barcelona, Spain
| | - P Cerdà
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Internal Medicine Department, Hospital Universitari Bellvitge, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
| | - F Cruellas
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.,Otorhinolaryngology Department, Hospital Universitari Bellvitge, Barcelona, Spain
| | - Q Ordi
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.,Radiology Department, Hospital Universitari Bellvitge, Barcelona, Spain
| | - X Corbella
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Internal Medicine Department, Hospital Universitari Bellvitge, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.,Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain
| | - J Ribas
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.,Pneumology Department, Hospital Universitari Bellvitge, Barcelona, Spain
| | - J Castellote
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain.,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.,Liver Transplant Unit, Department of Digestive Diseases, Hospital Universitari Bellvitge, Barcelona, Spain.,Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain
| | - A Riera-Mestre
- HHT Unit, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n. L'Hospitalet de Llobregat, 08907, Barcelona, Spain. .,Internal Medicine Department, Hospital Universitari Bellvitge, Barcelona, Spain. .,Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. .,Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.
| |
Collapse
|
3
|
Gubin TA, Iyer HP, Liew SN, Sarma A, Revelos A, Ribas J, Movassaghi B, Chu ZM, Khalid AN, Majmudar MD, Lee CX. A Systems Approach to Healthcare Innovation Using the MIT Hacking Medicine Model. Cell Syst 2019; 5:6-10. [PMID: 28750199 DOI: 10.1016/j.cels.2017.02.012] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2016] [Revised: 09/06/2016] [Accepted: 02/16/2017] [Indexed: 11/18/2022]
Abstract
MIT Hacking Medicine is a student, academic, and community-led organization that uses systems-oriented "healthcare hacking" to address challenges around innovation in healthcare. The group has organized more than 80 events around the world that attract participants with diverse backgrounds. These participants are trained to address clinical needs from the perspective of multiple stakeholders and emphasize utility and implementation viability of proposed solutions. We describe the MIT Hacking Medicine model as a potential method to integrate collaboration and training in rapid innovation techniques into academic medical centers. Built upon a systems approach to healthcare innovation, the time-compressed but expertly guided nature of the events could enable more widely accessible preliminary training in systems-level innovation methodology, as well as creating a structured opportunity for interdisciplinary congregation and collaboration.
Collapse
Affiliation(s)
- Tatyana A Gubin
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; Department of Mechanical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Building 3-173, Cambridge, MA, USA; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, USA
| | - Hari P Iyer
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA
| | - Shirlene N Liew
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; Department of System Design & Management, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Building E40-306, Cambridge, MA, USA
| | - Aartik Sarma
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA, USA
| | - Alex Revelos
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; Department of System Design & Management, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Building E40-306, Cambridge, MA, USA
| | - João Ribas
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, 77 Massachusetts Avenue, Building E25-518, Cambridge, MA, USA
| | - Babak Movassaghi
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; MIT Sloan School of Management, Massachusetts Institute of Technology, 30 Memorial Drive, Cambridge, MA, USA
| | - Zen M Chu
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; MIT Sloan School of Management, Massachusetts Institute of Technology, 30 Memorial Drive, Cambridge, MA, USA
| | - Ayesha N Khalid
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA, USA; Department of Otolaryngology, Cambridge Health Alliance, 1493 Cambridge Street, Cambridge, MA, USA
| | - Maulik D Majmudar
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, USA; Healthcare Transformation Lab, Corrigan Minehan Heart Center, Massachusetts General Hospital, Boston, MA, USA
| | - Christopher Xiang Lee
- MIT Hacking Medicine, Massachusetts Institute of Technology, 1 Amherst Street, Building E40-160, Cambridge, MA, USA; Harvard-MIT Division of Health Sciences and Technology, 77 Massachusetts Avenue, Building E25-518, Cambridge, MA, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, USA.
| |
Collapse
|
4
|
Abstract
The field of microphysiological systems (or organs-on-a-chip) experienced, in the past decade, a surge in publications and efforts towards commercialization. Such systems hold the promise to advance drug discovery, diagnostics, and many other areas. In this review we summarize and analyze the current status of the field, describe the commercial advances and discuss standing challenges and the commercial outlook of the field.
Collapse
Affiliation(s)
- João Ribas
- Doctoral Program in Experimental Biology and Biomedicine, Center for Neuroscience and Cell Biology, Institute for Interdisciplinary Research, University of Coimbra, 3030-789 Coimbra, Portugal
| | | | - Jeroen Rouwkema
- Department of Biomechanical Engineering, Technical Medical Centre, University of Twente, Enschede, The Netherlands
| |
Collapse
|
5
|
Ramatowski JW, Lee CX, Mantzavino A, Ribas J, Guerra W, Preston ND, Schernhammer E, Madoff LC, Lassmann B. Planning an innovation marathon at an infectious disease conference with results from the International Meeting on Emerging Diseases and Surveillance 2016 Hackathon. Int J Infect Dis 2017; 65:93-97. [PMID: 29017856 PMCID: PMC7110634 DOI: 10.1016/j.ijid.2017.09.025] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Revised: 08/23/2017] [Accepted: 09/26/2017] [Indexed: 11/26/2022] Open
Abstract
Hackathon at infectious disease meeting. Interdisciplinary collaboration. Novel solutions.
A hackathon is best described as an ‘innovation marathon’. Derived from the words ‘hacking’ and ‘marathon’, it brings together multidisciplinary teams to collaborate intensely over a short period of time to define a problem, devise a solution, and design a working prototype. International scientific meetings are conducive to successful hackathons, providing an audience of expert professionals who describe challenges and ensure the proposed solutions address end-user needs. Collaborations with local organizations and academic centers are crucial to attracting complementary specialties such as IT advisors, engineers, and entrepreneurs to develop sustainable projects. The core process of first identifying and deconstructing a problem followed by solution iteration is applicable to challenges at workplaces around the world. Ultimately, this model can be used to drive innovation and catalyze change in the global health community. The planning, execution, and outcomes of a hackathon event organized in conjunction with the International Meeting on Emerging Diseases and Surveillance (IMED 2016) are described in this article. Physicians, public health practitioners, veterinarians, IT professionals, engineers, and entrepreneurs came together for 2 days to develop solutions at the intersection of emerging infectious diseases and climate change. Projects that resulted from the IMED 2016 Hackathon included environmental impact assessment software for humanitarian organization relief efforts; enhanced communication tools to prevent disease outbreaks; a participatory mobile application to speed the elimination of rabies in Indonesia; integrated disease surveillance platforms; and an improved search function for infectious disease outbreak reports in the ProMED-mail network.
Collapse
Affiliation(s)
| | - Christopher Xiang Lee
- MIT Hacking Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Aikaterini Mantzavino
- MIT Hacking Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - João Ribas
- MIT Hacking Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA; Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Winter Guerra
- MIT Hacking Medicine, Massachusetts Institute of Technology, Cambridge, MA, USA; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA
| | | | - Eva Schernhammer
- Department of Epidemiology, Center for Public Health, Medical University of Vienna, Vienna, Austria; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Lawrence C Madoff
- International Society for Infectious Diseases, Brookline, MA, USA; Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA
| | - Britta Lassmann
- International Society for Infectious Diseases, Brookline, MA, USA
| |
Collapse
|
6
|
Ribas J, Zhang YS, Pitrez PR, Leijten J, Miscuglio M, Rouwkema J, Dokmeci MR, Nissan X, Ferreira L, Khademhosseini A. Biomechanical Strain Exacerbates Inflammation on a Progeria-on-a-Chip Model. Small 2017; 13:10.1002/smll.201603737. [PMID: 28211642 PMCID: PMC5545787 DOI: 10.1002/smll.201603737] [Citation(s) in RCA: 55] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Revised: 01/02/2017] [Indexed: 05/22/2023]
Abstract
Organ-on-a-chip platforms seek to recapitulate the complex microenvironment of human organs using miniaturized microfluidic devices. Besides modeling healthy organs, these devices have been used to model diseases, yielding new insights into pathophysiology. Hutchinson-Gilford progeria syndrome (HGPS) is a premature aging disease showing accelerated vascular aging, leading to the death of patients due to cardiovascular diseases. HGPS targets primarily vascular cells, which reside in mechanically active tissues. Here, a progeria-on-a-chip model is developed and the effects of biomechanical strain are examined in the context of vascular aging and disease. Physiological strain induces a contractile phenotype in primary smooth muscle cells (SMCs), while a pathological strain induces a hypertensive phenotype similar to that of angiotensin II treatment. Interestingly, SMCs derived from human induced pluripotent stem cells of HGPS donors (HGPS iPS-SMCs), but not from healthy donors, show an exacerbated inflammatory response to strain. In particular, increased levels of inflammation markers as well as DNA damage are observed. Pharmacological intervention reverses the strain-induced damage by shifting gene expression profile away from inflammation. The progeria-on-a-chip is a relevant platform to study biomechanics in vascular biology, particularly in the setting of vascular disease and aging, while simultaneously facilitating the discovery of new drugs and/or therapeutic targets.
Collapse
Affiliation(s)
- João Ribas
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA, Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Doctoral Program in Experimental Biology and Biomedicine, Center for Neuroscience and Cell Biology, Institute for Interdisciplinary Research, University of Coimbra, 3030-789 Coimbra, Portugal
| | - Yu Shrike Zhang
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA, Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
| | - Patrícia R. Pitrez
- CNC-Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal, Institute for Interdisciplinary Research, University of Coimbra, 3030-789 Coimbra, Portugal
| | - Jeroen Leijten
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA, Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Department of Developmental BioEngineering, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
| | - Mario Miscuglio
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA, Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jeroen Rouwkema
- Department of Biomechanical Engineering, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
| | - Mehmet Remzi Dokmeci
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA, Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
| | - Xavier Nissan
- INSERM U861, I-STEM, AFM, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases, Evry Cedex 91030, France
| | | | | |
Collapse
|
7
|
Zhang YS, Aleman J, Shin SR, Kilic T, Kim D, Mousavi Shaegh SA, Massa S, Riahi R, Chae S, Hu N, Avci H, Zhang W, Silvestri A, Sanati Nezhad A, Manbohi A, De Ferrari F, Polini A, Calzone G, Shaikh N, Alerasool P, Budina E, Kang J, Bhise N, Ribas J, Pourmand A, Skardal A, Shupe T, Bishop CE, Dokmeci MR, Atala A, Khademhosseini A. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci U S A 2017; 114:E2293-E2302. [PMID: 28265064 PMCID: PMC5373350 DOI: 10.1073/pnas.1612906114] [Citation(s) in RCA: 427] [Impact Index Per Article: 61.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Organ-on-a-chip systems are miniaturized microfluidic 3D human tissue and organ models designed to recapitulate the important biological and physiological parameters of their in vivo counterparts. They have recently emerged as a viable platform for personalized medicine and drug screening. These in vitro models, featuring biomimetic compositions, architectures, and functions, are expected to replace the conventional planar, static cell cultures and bridge the gap between the currently used preclinical animal models and the human body. Multiple organoid models may be further connected together through the microfluidics in a similar manner in which they are arranged in vivo, providing the capability to analyze multiorgan interactions. Although a wide variety of human organ-on-a-chip models have been created, there are limited efforts on the integration of multisensor systems. However, in situ continual measuring is critical in precise assessment of the microenvironment parameters and the dynamic responses of the organs to pharmaceutical compounds over extended periods of time. In addition, automated and noninvasive capability is strongly desired for long-term monitoring. Here, we report a fully integrated modular physical, biochemical, and optical sensing platform through a fluidics-routing breadboard, which operates organ-on-a-chip units in a continual, dynamic, and automated manner. We believe that this platform technology has paved a potential avenue to promote the performance of current organ-on-a-chip models in drug screening by integrating a multitude of real-time sensors to achieve automated in situ monitoring of biophysical and biochemical parameters.
Collapse
Affiliation(s)
- Yu Shrike Zhang
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139;
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115
| | - Julio Aleman
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157
| | - Su Ryon Shin
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115
| | - Tugba Kilic
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Department of Biomedical Engineering, Faculty of Engineering and Architecture, Izmir Katip Celebi University, Izmir 35620, Turkey
| | - Duckjin Kim
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
| | - Seyed Ali Mousavi Shaegh
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Orthopaedic Research Center, Mashhad University of Medical Sciences, Mashhad 9176699199, Iran
| | - Solange Massa
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Graduate School Program in Biomedicine, Universidad de los Andes, Santiago 7620001, Chile
| | - Reza Riahi
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
| | - Sukyoung Chae
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
| | - Ning Hu
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Biosensor National Special Laboratory, Key Laboratory of Biomedical Engineering of Education Ministry, Department of Biomedical Engineering, Zhejiang University, Hangzhou 310027, People's Republic of China
| | - Huseyin Avci
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Metallurgical and Materials Engineering Department, Faculty of Engineering and Architecture, Eskisehir Osmangazi University, Eskisehir 26030, Turkey
| | - Weijia Zhang
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, People's Republic of China
| | - Antonia Silvestri
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Department of Electronics and Telecommunications, Polytechnic University of Turin, Turin 10129, Italy
| | - Amir Sanati Nezhad
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- BioMEMS and Bioinspired Microfluidics Laboratory, Center for Bioengineering Research and Education, Department of Mechanical and Manufacturing Engineering, University of Calgary, Calgary, AB T2N 1N4, Canada
| | - Ahmad Manbohi
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Department of Marine Science, Iranian National Institute for Oceanography and Atmospheric Science, Tehran 1411813389, Iran
| | - Fabio De Ferrari
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Department of Electronics and Telecommunications, Polytechnic University of Turin, Turin 10129, Italy
| | - Alessandro Polini
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
| | - Giovanni Calzone
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
| | - Noor Shaikh
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Division of Engineering Science, Faculty of Applied Science and Engineering, University of Toronto, Toronto, ON, Canada M5S 1A4
| | - Parissa Alerasool
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
| | - Erica Budina
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
| | - Jian Kang
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
| | - Nupura Bhise
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
| | - João Ribas
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Doctoral Program in Experimental Biology and Biomedicine, Center for Neuroscience and Cell Biology, Institute for Interdisciplinary Research, University of Coimbra, Coimbra 3030-789, Portugal
| | - Adel Pourmand
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Department of Electrical Engineering, Sahand University of Technology, Tabriz 5331711111, Iran
| | - Aleksander Skardal
- Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157
| | - Thomas Shupe
- Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157
| | - Colin E Bishop
- Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157
| | - Mehmet Remzi Dokmeci
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115
| | - Anthony Atala
- Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27157
| | - Ali Khademhosseini
- Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02139;
- Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Cambridge, MA 02139
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115
- Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Seoul 143-701, Republic of Korea
- Center for Nanotechnology, King Abdulaziz University, Jeddah 21569, Saudi Arabia
| |
Collapse
|
8
|
Newman P, Galenano Niño JL, Graney P, Razal JM, Minett AI, Ribas J, Ovalle-Robles R, Biro M, Zreiqat H. Relationship between nanotopographical alignment and stem cell fate with live imaging and shape analysis. Sci Rep 2016; 6:37909. [PMID: 27910868 PMCID: PMC5133629 DOI: 10.1038/srep37909] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2016] [Accepted: 11/02/2016] [Indexed: 12/14/2022] Open
Abstract
The topography of a biomaterial regulates cellular interactions and determine stem cell fate. A complete understanding of how topographical properties affect cell behavior will allow the rational design of material surfaces that elicit specified biological functions once placed in the body. To this end, we fabricate substrates with aligned or randomly organized fibrous nanostructured topographies. Culturing adipose-derived stem cells (ASCs), we explore the dynamic relationship between the alignment of topography, cell shape and cell differentiation to osteogenic and myogenic lineages. We show aligned topographies differentiate cells towards a satellite cell muscle progenitor state - a distinct cell myogenic lineage responsible for postnatal growth and repair of muscle. We analyze cell shape between the different topographies, using fluorescent time-lapse imaging over 21 days. In contrast to previous work, this allows the direct measurement of cell shape at a given time rather than defining the morphology of the underlying topography and neglecting cell shape. We report quantitative metrics of the time-based morphological behaviors of cell shape in response to differing topographies. This analysis offers insights into the relationship between topography, cell shape and cell differentiation. Cells differentiating towards a myogenic fate on aligned topographies adopt a characteristic elongated shape as well as the alignment of cells.
Collapse
Affiliation(s)
- Peter Newman
- Biomaterials and Tissue Engineering Research Unit, School of Aeronautical Mechanical and Mechatronics Engineering, University of Sydney, Sydney, NSW, 2006, Australia
| | - Jorge Luis Galenano Niño
- EMBL Australia node in Single Molecule Science, School of Medical Sciences, The University of New South Wales, Sydney, Australia
| | - Pamela Graney
- Department of Biomedical Engineering, School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA 19104, USA
| | - Joselito M Razal
- Institute for Frontier Materials, Deakin University, Geelong, Victoria, 3216, Australia
| | - Andrew I Minett
- Laboratory for Sustainable Technology, Department of Chemical and Biomolecular Engineering, University of Sydney, NSW, 2006, Australia.,Australian Institute for Nanoscale Science and Technology, University of Sydney, NSW, 2006, Australia
| | - João Ribas
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA
| | - Raquel Ovalle-Robles
- Nano-Science &Technology Center, LINTEC of America Inc., Richardson, Texas 75081, USA
| | - Maté Biro
- EMBL Australia node in Single Molecule Science, School of Medical Sciences, The University of New South Wales, Sydney, Australia.,Sydney Medical School, The University of Sydney, NSW, 2006, Australia
| | - Hala Zreiqat
- Biomaterials and Tissue Engineering Research Unit, School of Aeronautical Mechanical and Mechatronics Engineering, University of Sydney, Sydney, NSW, 2006, Australia
| |
Collapse
|
9
|
Abstract
It has been stated that cyclosporin and nifedipine produce gingival overgrowth. However, the specific pathogenic mechanism remains uncertain. We used an experimental rat model to test the hypothesis that changes in collagen metabolism and numbers of gingival blood vessels are not mediated by intracellular calcium concentration (ratiometric Fura-2 AM measurement) in gingival fibroblasts. In the cyclosporin group, both width (364.2 ± 67.5 μm) and microvessel density (number of vessels/mm2, stained with anti-CD34 antibody) (41.6 ± 5.1) of gingiva were statistically different when compared with those in the control group (width = 184.3 ± 35.2 μm, microvessel density = 19.6 ± 2.4). The nifedipine group showed the highest content of collagen (proportion of total stroma occupied by collagen, stained with Picro-Mallory) (nifedipine group = 66.3 ± 9.4, cyclosporin group = 55.2 ± 7.9, control group = 30.1 ± 10.2). Freshly cultured fibroblasts from the cyclosporin group exhibited higher ratiometric values of fluorescence than did both the control and nifedipine groups (p = 0.03). Our results support the hypothesis that changes in gingival collagen metabolism are not mediated by calcium intracellular oscillations.
Collapse
Affiliation(s)
- P Bullon
- Department of Periodontology, Facultad de Odontologia, University of Sevilla, c/Avicena s/n, 41009 Sevilla, Spain.
| | | | | | | | | | | | | |
Collapse
|
10
|
Alves CJ, Alencastre IS, Neto E, Ribas J, Ferreira S, Vasconcelos DM, Sousa DM, Summavielle T, Lamghari M. Bone Injury and Repair Trigger Central and Peripheral NPY Neuronal Pathways. PLoS One 2016; 11:e0165465. [PMID: 27802308 PMCID: PMC5089690 DOI: 10.1371/journal.pone.0165465] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Accepted: 10/12/2016] [Indexed: 11/21/2022] Open
Abstract
Bone repair is a specialized type of wound repair controlled by complex multi-factorial events. The nervous system is recognized as one of the key regulators of bone mass, thereby suggesting a role for neuronal pathways in bone homeostasis. However, in the context of bone injury and repair, little is known on the interplay between the nervous system and bone. Here, we addressed the neuropeptide Y (NPY) neuronal arm during the initial stages of bone repair encompassing the inflammatory response and ossification phases in femoral-defect mouse model. Spatial and temporal analysis of transcriptional and protein levels of NPY and its receptors, Y1R and Y2R, reported to be involved in bone homeostasis, was performed in bone, dorsal root ganglia (DRG) and hypothalamus after femoral injury. The results showed that NPY system activity is increased in a time- and space-dependent manner during bone repair. Y1R expression was trigged in both bone and DRG throughout the inflammatory phase, while a Y2R response was restricted to the hypothalamus and at a later stage, during the ossification step. Our results provide new insights into the involvement of NPY neuronal pathways in bone repair.
Collapse
Affiliation(s)
- Cecília J. Alves
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
- Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Porto, Portugal
| | - Inês S. Alencastre
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
- Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Porto, Portugal
| | - Estrela Neto
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
- Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Porto, Portugal
- Faculdade de Medicina, Universidade do Porto (FMUP), Porto, Portugal
| | - João Ribas
- Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Porto, Portugal
| | - Sofia Ferreira
- Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Porto, Portugal
| | - Daniel M. Vasconcelos
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
- Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Porto, Portugal
- Instituto Ciências Biomédicas Abel Salazar (ICBAS), Universidade de Porto, Porto, Portugal
| | - Daniela M. Sousa
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
- Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Porto, Portugal
| | - Teresa Summavielle
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
- Instituto de Biologia Molecular e Celular (IBMC), Universidade do Porto, Porto, Portugal
- Escola Superior de Tecnologia da Saúde do Porto, Instituto Politécnico do Porto, Porto, Portugal
| | - Meriem Lamghari
- Instituto de Investigação e Inovação em Saúde (i3S), Universidade do Porto, Porto, Portugal
- Instituto de Engenharia Biomédica (INEB), Universidade do Porto, Porto, Portugal
- Instituto Ciências Biomédicas Abel Salazar (ICBAS), Universidade de Porto, Porto, Portugal
- * E-mail:
| |
Collapse
|
11
|
Ribas J, Sadeghi H, Manbachi A, Leijten J, Brinegar K, Zhang YS, Ferreira L, Khademhosseini A. Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development. ACTA ACUST UNITED AC 2016; 2:82-96. [PMID: 28971113 DOI: 10.1089/aivt.2016.0002] [Citation(s) in RCA: 98] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Cardiovascular diseases are prevalent worldwide and are the most frequent causes of death in the United States. Although spending in drug discovery/development has increased, the amount of drug approvals has seen a progressive decline. Particularly, adverse side effects to the heart and general vasculature have become common causes for preclinical project closures, and preclinical models do not fully recapitulate human in vivo dynamics. Recently, organs-on-a-chip technologies have been proposed to mimic the dynamic conditions of the cardiovascular system-in particular, heart and general vasculature. These systems pay particular attention to mimicking structural organization, shear stress, transmural pressure, mechanical stretching, and electrical stimulation. Heart- and vasculature-on-a-chip platforms have been successfully generated to study a variety of physiological phenomena, model diseases, and probe the effects of drugs. Here, we review and discuss recent breakthroughs in the development of cardiovascular organs-on-a-chip platforms, and their current and future applications in the area of drug discovery and development.
Collapse
Affiliation(s)
- João Ribas
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts.,Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts.,Doctoral Program in Experimental Biology and Biomedicine, Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal
| | - Hossein Sadeghi
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts.,Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts.,Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Amir Manbachi
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts.,Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts
| | - Jeroen Leijten
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts.,Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts.,Department of Developmental BioEngineering, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, The Netherlands
| | - Katelyn Brinegar
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts.,Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts
| | - Yu Shrike Zhang
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts.,Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts
| | - Lino Ferreira
- CNC-Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.,Institute for Interdisciplinary Research, University of Coimbra, Coimbra, Portugal
| | - Ali Khademhosseini
- Biomaterials Innovation Research Center, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, Massachusetts.,Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts.,Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts.,Department of Physics, King Abdulaziz University, Jeddah, Saudi Arabia.,Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Seoul, Republic of Korea
| |
Collapse
|
12
|
Zhang W, Zhang YS, Bakht SM, Aleman J, Shin SR, Yue K, Sica M, Ribas J, Duchamp M, Ju J, Sadeghian RB, Kim D, Dokmeci MR, Atala A, Khademhosseini A. Elastomeric free-form blood vessels for interconnecting organs on chip systems. Lab Chip 2016; 16:1579-86. [PMID: 26999423 PMCID: PMC4846563 DOI: 10.1039/c6lc00001k] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Conventional blood vessel-on-a-chip models are typically based on microchannel-like structures enclosed within bulk elastomers such as polydimethylsiloxane (PDMS). However, these bulk vascular models largely function as individual platforms and exhibit limited flexibility particularly when used in conjunction with other organ modules. Oftentimes, lengthy connectors and/or tubes are still needed to interface multiple chips, resulting in a large waste volume counterintuitive to the miniaturized nature of organs-on-chips. In this work, we report the development of a novel form of a vascular module based on PDMS hollow tubes, which closely emulates the morphology and properties of human blood vessels to integrate multiple organs-on-chips. Specifically, we present two templating strategies to fabricate hollow PDMS tubes with adjustable diameters and wall thicknesses, where metal rods or airflow were employed as the inner templates, while plastic tubes were used as the outer template. The PDMS tubes could then be functionalized by human umbilical vein endothelial cells (HUVECs) in their interior surfaces to further construct elastomeric biomimetic blood vessels. The endothelium developed biofunctionality as demonstrated by the expression of an endothelial biomarker (CD31) as well as dose-dependent responses in the secretion of von Willebrand factor and nitric oxide upon treatment with pharmaceutical compounds. We believe that with their clear advantages including high optical transparency, gas permeability, and tunable elasticity matching those of native blood vessels, these free-form PDMS vascular modules can supplement bulk vascular organoids and likely replace inert plastic tubes in integrating multiple organoids into a single microfluidic circuitry.
Collapse
Affiliation(s)
- Weijia Zhang
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Shanghai Ocean University, Shanghai, 201306, PR China
| | - Yu Shrike Zhang
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, MA 02139, USA
| | - Syeda Mahwish Bakht
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and COMSATS Institute of Information and Technology, Islamabad 45550, Pakistan
| | - Julio Aleman
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Su Ryon Shin
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, MA 02139, USA
| | - Kan Yue
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Marco Sica
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Department of Biomedical Engineering, Politecnico di Torino, Torino 10129, Italy
| | - João Ribas
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Doctoral Programme in Experimental Biology and Biomedicine, Center for Neuroscience and Cell Biology, Institute for Interdisciplinary Research, University of Coimbra, Coimbra 3030-789, Portugal and Biocant-Biotechnology Innovation Center, Cantanhede 3060-197, Portugal
| | - Margaux Duchamp
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Department of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland
| | - Jie Ju
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Ramin Banan Sadeghian
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and WPI-Advanced Institute for Materials Research, Tohoku University, Sendai 980-8578, Japan
| | - Duckjin Kim
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Mehmet Remzi Dokmeci
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Wyss Institute for Biologically Inspired Engineering, Harvard University, Cambridge, MA 02139, USA
| | - Anthony Atala
- Wake Forest Institute for Regenerative Medicine, Winston-Salem, NC 27101, USA
| | - Ali Khademhosseini
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA. and Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA and Department of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne 1015, Switzerland and Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Seoul 143-701, Republic of Korea and Department of Physics, King Abdulaziz University, Jeddah 21569, Saudi Arabia
| |
Collapse
|
13
|
Masoudi E, Ribas J, Kaushik G, Leijten J, Khademhosseini A. Platelet-Rich Blood Derivatives for Stem Cell-Based Tissue Engineering and Regeneration. Curr Stem Cell Rep 2016; 2:33-42. [PMID: 27047733 DOI: 10.1007/s40778-016-0034-8] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Platelet rich blood derivatives have been widely used in different fields of medicine and stem cell based tissue engineering. They represent natural cocktails of autologous growth factor, which could provide an alternative for recombinant protein based approaches. Platelet rich blood derivatives, such as platelet rich plasma, have consistently shown to potentiate stem cell proliferation, migration, and differentiation. Here, we review the spectrum of platelet rich blood derivatives, discuss their current applications in tissue engineering and regenerative medicine, reflect on their effect on stem cells, and highlight current translational challenges.
Collapse
Affiliation(s)
- Elham Masoudi
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Medicine, Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA
| | - João Ribas
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Medicine, Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.,Doctoral Program in Experimental Biology and Biomedicine, Center for Neuroscience and Cell Biology, Institute for Interdisciplinary Research, University of Coimbra, 3030-789 Coimbra, Portugal
| | - Gaurav Kaushik
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Medicine, Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA
| | - Jeroen Leijten
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Medicine, Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA
| | - Ali Khademhosseini
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.,Department of Medicine, Biomaterials Innovation Research Center, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.,Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA.,Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Hwayang-dong, Gwangjin-gu, Seoul 143-701, Republic of Korea.,Department of Physics, King Abdulaziz University, Jeddah 21569, Saudi Arabia
| |
Collapse
|
14
|
González-Badillo JJ, Rodríguez-Rosell D, Sánchez-Medina L, Ribas J, López-López C, Mora-Custodio R, Yañez-García JM, Pareja-Blanco F. Short-term Recovery Following Resistance Exercise Leading or not to Failure. Int J Sports Med 2015; 37:295-304. [PMID: 26667923 DOI: 10.1055/s-0035-1564254] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
This study analyzed the time course of recovery following 2 resistance exercise protocols differing in level of effort: maximum (to failure) vs. half-maximum number of repetitions per set. 9 males performed 3 sets of 4 vs. 8 repetitions with their 80% 1RM load, 3×4(8) vs. 3×8(8), in the bench press and squat. Several time-points from 24 h pre- to 48 h post-exercise were established to assess the mechanical (countermovement jump height, CMJ; velocity against the 1 m·s(-1) load, V1-load), biochemical (testosterone, cortisol, GH, prolactin, IGF-1, CK) and heart rate variability (HRV) and complexity (HRC) response to exercise. 3×8(8) resulted in greater neuromuscular fatigue (higher reductions in repetition velocity and velocity against V1-load) than 3×4(8). CMJ remained reduced up to 48 h post-exercise following 3×8(8), whereas it was recovered after 6 h for 3×4(8). Significantly greater prolactin and IGF-1 levels were found for 3×8(8) vs. 3×4(8). Significant reductions in HRV and HRC were observed for 3×8(8) vs. 3×4(8) in the immediate recovery. Performing a half-maximum number of repetitions per set resulted in: 1) a stimulus of faster mean repetition velocities; 2) lower impairment of neuromuscular performance and faster recovery; 3) reduced hormonal response and muscle damage; and 4) lower reduction in HRV and HRC following exercise.
Collapse
Affiliation(s)
- J J González-Badillo
- Sports and Athletic Performance Research Centre. Faculty of Sport. Pablo de Olavide University, Seville, Spain
| | - D Rodríguez-Rosell
- Sports and Athletic Performance Research Centre. Faculty of Sport. Pablo de Olavide University, Seville, Spain
| | - L Sánchez-Medina
- Instituto Navarro de Deporte y Juventud (INDJ), Studies, Research and Sports Medicine Centre, Pamplona, Spain
| | - J Ribas
- Medical Physiology and Biophysics Department. University of Seville, Spain
| | - C López-López
- Junta de Andalucía, Centro Andaluz de Medicina del Deporte, Seville, Spain
| | - R Mora-Custodio
- Sports and Athletic Performance Research Centre. Faculty of Sport. Pablo de Olavide University, Seville, Spain
| | - J M Yañez-García
- Sports and Athletic Performance Research Centre. Faculty of Sport. Pablo de Olavide University, Seville, Spain
| | - F Pareja-Blanco
- Sports and Athletic Performance Research Centre. Faculty of Sport. Pablo de Olavide University, Seville, Spain
| |
Collapse
|
15
|
Yeung JC, Ribas J, De Campos M, Ko M, Blitz M, Compeau C. F-030OUTCOMES FOLLOWING REVISION PECTUS EXCAVATUM REPAIR IN THE ADULT. Interact Cardiovasc Thorac Surg 2015. [DOI: 10.1093/icvts/ivv204.30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Zhang YS, Ribas J, Nadhman A, Aleman J, Selimović Š, Lesher-Perez SC, Wang T, Manoharan V, Shin SR, Damilano A, Annabi N, Dokmeci MR, Takayama S, Khademhosseini A. A cost-effective fluorescence mini-microscope for biomedical applications. Lab Chip 2015; 15:3661-9. [PMID: 26282117 PMCID: PMC4550514 DOI: 10.1039/c5lc00666j] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
We have designed and fabricated a miniature microscope from off-the-shelf components and a webcam, with built-in fluorescence capability for biomedical applications. The mini-microscope was able to detect both biochemical parameters, such as cell/tissue viability (e.g. live/dead assay), and biophysical properties of the microenvironment such as oxygen levels in microfabricated tissues based on an oxygen-sensitive fluorescent dye. This mini-microscope has adjustable magnifications from 8-60×, achieves a resolution as high as <2 μm, and possesses a long working distance of 4.5 mm (at a magnification of 8×). The mini-microscope was able to chronologically monitor cell migration and analyze beating of microfluidic liver and cardiac bioreactors in real time, respectively. The mini-microscope system is cheap, and its modularity allows convenient integration with a wide variety of pre-existing platforms including, but not limited to, cell culture plates, microfluidic devices, and organs-on-a-chip systems. Therefore, we envision its widespread application in cell biology, tissue engineering, biosensing, microfluidics, and organs-on-chips, which can potentially replace conventional bench-top microscopy where long-term in situ and large-scale imaging/analysis is required.
Collapse
Affiliation(s)
- Yu Shrike Zhang
- Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Vicente R, Ribas J, Zanchini C, Gatteschi D, Legros JP, Faulmann C, Cassoux P. Molecular and Crystal Structure, and EPR Studies of Tetraphenylarsonium [Bis-(1,3-dithia-2-one-4,5-dithiolato)-nickelate], (AsPh4)[Ni(dmid)2]. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/znb-1988-0909] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
The crystal structure of (AsPh4)[Ni(dmid)2 (dmid2- = 1,3-dithia-2-one-4,5-dithiolato) has been determined by X-ray diffraction studies: crystals are monoclinic, space group P21/n a = 14.724(2), b = 14.305(5), c = 15.570(3) Å, β = 92.20(1)°, V = 3277 Å3 , ᵨx = 1.63 g cm-3 for Z = 4, final conventional agreement indices R = 0.038 and Rw = 0.049 for 2115 unique, observed reflections and 211 variable parameters. The asymmetric unit contains one (AsPh4)+ cation and one [Ni(dmid)2] anion, both in general positions. The anions are isolated from each other by the bulky cations. The [Ni(dmid)2]- ion deviates strongly from planarity: the dihedral angle between the two Ni(dmid) moieties is 10.7°; one of the dmid ligand is almost planar, while the second one is severely puckered. Polycristalline powder and single crystal EPR spectra have been recorded at room temperature. Only one signal was observed in all crystal orientations. The angular depend-ences of the linewidth and of the g values have been determined, as well as the principal g values and directions. These results have been compared to those previously obtained for the analogue (n-Bu4N)[Ni(dmit)2 ] (drnit2- = 1,3-dithia-2-thione-4,5-dithiolato), and discussed in terms of the localization of the unpaired electron on the ligands. leading to a formal (III) and actual (II) nickel oxidation state.
Collapse
Affiliation(s)
- R. Vicente
- Departament de Quimica Inorganica. Faeultat de Q u i m i c a , Universität de Barcelona, Diagonal 647, 08028 Barcelona, Spain
| | - J. Ribas
- Departament de Quimica Inorganica. Faeultat de Q u i m i c a , Universität de Barcelona, Diagonal 647, 08028 Barcelona, Spain
| | - C. Zanchini
- Dipartimento di Chimica, Universitä degli Studi di Firenze. Via Maragliano 75/77, 50144 Firenze, Italy
| | - D. Gatteschi
- Dipartimento di Chimica, Universitä degli Studi di Firenze. Via Maragliano 75/77, 50144 Firenze, Italy
| | - J.-P. Legros
- Laboratoire de Chimie de Coordination du CNRS, Unité 8241 associée à l'Université Paul-Sabatier, 205 route de Narbonne, 31077 Toulouse Cedex, France
| | - C. Faulmann
- Laboratoire de Chimie de Coordination du CNRS, Unité 8241 associée à l'Université Paul-Sabatier, 205 route de Narbonne, 31077 Toulouse Cedex, France
| | - P. Cassoux
- Laboratoire de Chimie de Coordination du CNRS, Unité 8241 associée à l'Université Paul-Sabatier, 205 route de Narbonne, 31077 Toulouse Cedex, France
| |
Collapse
|
18
|
Bhise NS, Ribas J, Manoharan V, Zhang YS, Polini A, Massa S, Dokmeci MR, Khademhosseini A. Organ-on-a-chip platforms for studying drug delivery systems. J Control Release 2014; 190:82-93. [PMID: 24818770 DOI: 10.1016/j.jconrel.2014.05.004] [Citation(s) in RCA: 235] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Revised: 04/24/2014] [Accepted: 05/02/2014] [Indexed: 01/03/2023]
Abstract
Novel microfluidic tools allow new ways to manufacture and test drug delivery systems. Organ-on-a-chip systems - microscale recapitulations of complex organ functions - promise to improve the drug development pipeline. This review highlights the importance of integrating microfluidic networks with 3D tissue engineered models to create organ-on-a-chip platforms, able to meet the demand of creating robust preclinical screening models. Specific examples are cited to demonstrate the use of these systems for studying the performance of drug delivery vectors and thereby reduce the discrepancies between their performance at preclinical and clinical trials. We also highlight the future directions that need to be pursued by the research community for these proof-of-concept studies to achieve the goal of accelerating clinical translation of drug delivery nanoparticles.
Collapse
Affiliation(s)
- Nupura S Bhise
- Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, 02139, USA
| | - João Ribas
- Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, 02139, USA; Doctoral Programme in Experimental Biology and Biomedicine, Center for Neuroscience and Cell Biology, Institute for Interdisciplinary Research, University of Coimbra, 3030-789 Coimbra, Portugal; Biocant - Biotechnology Innovation Center, 3060-197 Cantanhede, Portugal
| | - Vijayan Manoharan
- Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, 02139, USA
| | - Yu Shrike Zhang
- Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, 02139, USA
| | - Alessandro Polini
- Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, 02139, USA
| | - Solange Massa
- Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, 02139, USA
| | - Mehmet R Dokmeci
- Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, 02139, USA
| | - Ali Khademhosseini
- Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston 02115, USA; Department of Physics, King Abdulaziz University, Jeddah 21569, Saudi Arabia.
| |
Collapse
|
19
|
Annabi N, Selimović Š, Cox JPA, Ribas J, Bakooshli MA, Heintze D, Weiss AS, Cropek D, Khademhosseini A. Hydrogel-coated microfluidic channels for cardiomyocyte culture. Lab Chip 2013; 13:3569-77. [PMID: 23728018 PMCID: PMC3744594 DOI: 10.1039/c3lc50252j] [Citation(s) in RCA: 88] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
The research areas of tissue engineering and drug development have displayed increased interest in organ-on-a-chip studies, in which physiologically or pathologically relevant tissues can be engineered to test pharmaceutical candidates. Microfluidic technologies enable the control of the cellular microenvironment for these applications through the topography, size, and elastic properties of the microscale cell culture environment, while delivering nutrients and chemical cues to the cells through continuous media perfusion. Traditional materials used in the fabrication of microfluidic devices, such as poly(dimethylsiloxane) (PDMS), offer high fidelity and high feature resolution, but do not facilitate cell attachment. To overcome this challenge, we have developed a method for coating microfluidic channels inside a closed PDMS device with a cell-compatible hydrogel layer. We have synthesized photocrosslinkable gelatin and tropoelastin-based hydrogel solutions that were used to coat the surfaces under continuous flow inside 50 μm wide, straight microfluidic channels to generate a hydrogel layer on the channel walls. Our observation of primary cardiomyocytes seeded on these hydrogel layers showed preferred attachment as well as higher spontaneous beating rates on tropoelastin coatings compared to gelatin. In addition, cellular attachment, alignment and beating were stronger on 5% (w/v) than on 10% (w/v) hydrogel-coated channels. Our results demonstrate that cardiomyocytes respond favorably to the elastic, soft tropoelastin culture substrates, indicating that tropoelastin-based hydrogels may be a suitable coating choice for some organ-on-a-chip applications. We anticipate that the proposed hydrogel coating method and tropoelastin as a cell culture substrate may be useful for the generation of elastic tissues, e.g. blood vessels, using microfluidic approaches.
Collapse
Affiliation(s)
- Nasim Annabi
- Center for Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts 02115, USA
| | - Šeila Selimović
- Center for Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | | | - João Ribas
- Center for Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
- PhD Programme in Experimental Biology and Biomedicine, CNC-Center for Neuroscience and Cell Biology and Institute for Interdisciplinary Research (IIIUC), University of Coimbra, 3030-789 Coimbra, Portugal
- Biocant - Center of Innovation in Biotechnology, 3060-197 Cantanhede, Portugal
| | - Mohsen Afshar Bakooshli
- Center for Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Déborah Heintze
- Center for Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
- Institute of Bioengineering and School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015, Lausanne, Switzerland
| | - Anthony S. Weiss
- School of Molecular Bioscience, University of Sydney, 2006, Australia
- Bosch Institute, University of Sydney, 2006, Australia
- Charles Perkins Centre, University of Sydney, 2006, Australia
| | - Donald Cropek
- US Army Corps of Engineers Construction Engineering Research Laboratory, Champaign, IL61822, USA
| | - Ali Khademhosseini
- Center for Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts 02139, USA
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
- Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts 02115, USA
| |
Collapse
|
20
|
Farré E, Villarón P, Soy D, Carcelero E, Ribas J. PHC-029 Vancomycin Pharmacokinetics in Alcohol and Intravenous Drug Abusers: Abstract PHC-029 Table 1. Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
21
|
Sotoca J, Rovira M, Codina C, Ribas J. GRP-043 Concurrent Use of Different Benzodiazepines in Different Healthcare Levels. Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
22
|
Sotoca J, Rovira M, Codina C, Ribas J. GRP-075 Gastroprotection with Non-Steroidal Anti-Inflammatory Drugs at Hospital Discharge: Do We Follow Local Guidelines? Eur J Hosp Pharm 2013. [DOI: 10.1136/ejhpharm-2013-000276.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
23
|
Zhao JP, Hu BW, Zhang XF, Yang Q, El Fallah MS, Ribas J, Bu XH. One Pot Synthesis of Heterometallic 3d−3d Azide Coordination Architectures: Effect of the Single-Ion Anisotropy. Inorg Chem 2010; 49:11325-32. [DOI: 10.1021/ic101089n] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jiong-Peng Zhao
- Department of Chemistry, Nankai University, Tianjin 300071, People's Republic of China
| | - Bo-Wen Hu
- Department of Chemistry, Nankai University, Tianjin 300071, People's Republic of China
| | - Xiao-Feng Zhang
- Department of Chemistry, Nankai University, Tianjin 300071, People's Republic of China
| | - Qian Yang
- Department of Chemistry, Nankai University, Tianjin 300071, People's Republic of China
| | - M. S. El Fallah
- Departament de Química Inorgànica, Universitat de Barcelona, Diagonal, 647, 08028-Barcelona, Spain
| | - J. Ribas
- Departament de Química Inorgànica, Universitat de Barcelona, Diagonal, 647, 08028-Barcelona, Spain
| | - Xian-He Bu
- Department of Chemistry, Nankai University, Tianjin 300071, People's Republic of China
| |
Collapse
|
24
|
Martín MT, Rovira M, Massanes M, del Cacho E, Carcelero E, Tuset M, Codina C, Miro JM, Gatell JM, Ribas J. [Analysis of the duration of and reasons for changing the first combination of antiretroviral therapy]. Farm Hosp 2010; 34:224-30. [PMID: 20663703 DOI: 10.1016/j.farma.2010.01.013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2009] [Accepted: 01/20/2010] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVE To determine the duration of and reasons behind changing the various combinations of drugs used for the initiation of antiretroviral treatment in naïve patients. METHODS A retrospective observational study that included all patients with HIV infection who started antiretroviral therapy in a high-tech university reference hospital during the period from 1 January 2003 and 31 December 2005. Patients were followed until 31 December 2008. To estimate the cumulative probability of discontinuation the Kaplan-Meier method was used. RESULTS A total of 441 patients were included. The average duration of the first treatment was 384 (interquartile interval 84-1290) days. The regimen based on non-nucleoside reverse transcriptase inhibitors and those that included as nucleosides abacavir or tenofovir in combination with lamivudine or emtricitabine showed a significantly longer duration than the rest. The main reasons for termination were the side effects, although in a lesser percentage than that obtained in previous studies. No associations were found between the rest of the characteristics of the patients or of the treatment and the risk of termination. DISCUSSION Although the duration of the first antiretroviral treatment remains short, currently fewer changes are made due to side effects and due to loss to follow-up. The reasons may be better tolerance and less complexity. However, more studies are needed to determine the benefits of one regimen or another, and to be able to generalise the results.
Collapse
Affiliation(s)
- M T Martín
- Servicio de Farmacia, Hospital Clínic Barcelona, Barcelona, España.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Matsumoto Y, Goto S, Hashimoto H, Kokeguchi S, Shiotani M, Okada H, Cohen - Bacrie P, Hazout A, Belloc S, De Mouzon J, Menezo Y, Dumont M, Junca AM, Cohen-Bacrie M, Alvarez S, Olivennes F, Prisant N, Weltin M, Geissler W, Clussmann C, Strowitzki T, Eggert-Kruse W, Endou Y, Fjii Y, Motoyama H, Quintana FQ, Zaloa Larreategui ZL, Iratxe Penalba IP, Sara Ortega SO, Monica Martin MM, Guillermo Quea GQ, Jose Serna JS, Showell MG, Brown J, Yazdani A, Stankiewicz MT, Hart RJ, Zumoffen C, Munuce MJ, Caille A, Ghersevich S, Lendinez AM, Perez-Nevot B, Palomares AR, Serrano Garballo A, Rodriguez A, Reche A, Mayor-Olea A, Ruiz-Galdon M, Reyes-Engel A, Mendiola J, Jorgensen N, Andersson AM, Calafat AM, Redmon JB, Drobnis EZ, Wang C, Sparks A, Thurston SW, Liu F, Swan SH, Tarasconi AC, Tarasconi BV, Tarasconi DV, Silva EMV, Fujii Y, Endou Y, Motoyama H, Crha I, Pribyl J, Skladal P, Zakova J, Ventruba P, Pohanka M, De La Fuente G, Pacheco A, Velasco JAG, Requena A, Pacheco Castro A, San Celestino Carchenilla M, Salvanes R, Arnanz A, Balmori C, Pellicer A, Garcia-Velasco JA, Hashimoto H, Ishikawa T, Goto S, Kokeguchi S, Fujisawa M, Shiotani M, Kranz S, Hersemeyer K, Hentrich A, Tinneberg HR, Konrad L, Simon L, Lutton D, McManus J, Lewis SEM, San Celestino Carchenilla M, Pacheco Castro A, Rubio S, Simon Sanjurjo P, Pellicer A, Garcia-Velasco JA, Lewis S, Lutton D, McManus J, Simon L, Buzzi J, Valcarcel A, Lombardi E, Oses R, Rawe V, Young E, Magendzo A, Lizama S, Duque G, Mackenna A, Lutton D, Simon L, McManus J, Lewis SEM, Monqaut A, Zavaleta C, Lopez G, Lafuente R, Brassesco M, Condorelli R, La Vignera S, La Rosa S, Barone N, Vicari E, Bellanca S, D'Agata R, Calogero AE, Enciso M, Iglesias M, Galan I, Gosalvez A, Gosalvez J, Curaba M, Poels J, Van Langendonckt A, Donnez J, Wyns C, Garcez M, Salvador M, Pasqualotto EB, Braga DPAF, Borges E, Pasqualotto FF, Aoki T, Figueira RCS, Maldonado LGL, Pasqualotto FF, Iaconelli A, Borges E, Frassini R, Mandelli J, Pasqualotto EB, Borges E, Figueira RCS, Braga DPAF, Pasqualotto FF, Borges E, Pasqualotto FF, Figueira RCS, Setti AS, Braga DPAF, Cortezzi SS, Iaconelli A, La Vignera S, Vicari E, Di Mauro M, Burrello N, Condorelli R, D'Agata R, Calogero AE, Kashir J, Jones C, Young C, Ruas M, Grasa P, Rietdorf K, Heytens E, Heindryckx B, Yoon SY, Fissore RA, Deane CM, Nikiforaki D, Tee ST, de Sutter P, Parrington J, Coward K, Visser L, Westerveld GH, van Daalen SKM, van der Veen F, Lombardi MP, Repping S, Cubillos S, Sanchez S, Pedraza J, Charria G, Aparicio H, Gongora A, Caldino F, Cuneo S, Ou JP, Zhao WE, Liu YF, Xu YW, Zhou CQ, Al-Asmar Pinar N, Peinado V, Gruhn J, Susiarjo M, Gil-Salom M, Martinez-Jabaloyas JM, Pellicer A, Remohi J, Rubio C, Hassold T, Peinado V, Al-Asmar N, Gruhn J, Rodrigo L, Gil-Salom M, Martinez-Jabaloyas JM, Pellicer A, Remohi J, Hassold TJ, Rubio C, Bungum M, Forsell N, Giwercman A, Amiri I, Sheikh N, Najafi R, Godarzi M, Farimani M, Makukh H, Tyrkus M, Zastavna D, Nakonechnuy A, Khayat SS, Schileiko LV, Kurilo LF, Garcia-Herrero S, Garrido N, Martinez-Conejero JA, Romany L, Pellicer A, Meseguer M, Dorphin B, Lefevre M, Gout C, Oger P, Yazbeck C, Rougier N, De Stefani S, Scala V, Benedetti S, Tagliamonte MC, Zavagnini E, Palini S, Bulletti C, Canestrari F, Subiran N, Pinto FM, Candenas ML, Agirregoitia E, Irazusta J, Cha EM, Lee JH, Park IH, Lee KH, Kim MH, Jensen MS, Rebordosa C, Thulstrup AM, Toft G, Sorensen HT, Bonde JP, Henriksen TB, Olsen J, Bosco L, Speciale M, Manno M, Amireh N, Roccheri MC, Cittadini E, Wu P, Lee YM, Chen HW, Tzeng CR, Llacer J, Ten J, Lledo B, Rodriguez-Arnedo A, Morales R, Bernabeu R, Garcia-Peiro A, Martinez-Heredia J, Oliver-Bonet M, Ribas J, Abad C, Amengual MJ, Gosalvez J, Navarro J, Benet J, Moutou C, Gardes N, Nicod JC, Becker N, Bailly MP, Galland I, Pirello O, Rongieres C, Wittemer C, Viville S, Elmahaishi W, Smith B, Doshi A, Serhal P, Harper JC, Rennemeier C, Kammerer U, Dietl J, Staib P, Elgmati K, Nomikos M, Theodoridou M, Calver B, Swann K, Lai FA, Georgiou I, Lazaros L, Xita N, Kaponis A, Plachouras N, Hatzi E, Zikopoulos K, Ferfouri F, Clement P, Molina Gomes D, Albert M, Bailly M, Wainer R, Selva J, Vialard F, Takisawa T, Usui K, Kyoya T, Shibuya Y, Hattori H, Sato Y, Ota M, Kyono K, Chiu PC, Lam KK, Lee CL, Chung MK, Huang VW, O WS, Tang F, Ho PC, Yeung WS, Kim CH, Lee JY, Kim SH, Suh CS, Shin YK, Kang YJ, Jung JH, Cha CY, Hwang ES, Mukaida T, Nagaba M, Takahashi K, Elkaffash D, Sedrak M, Huhtaniemi I, Abdel-Al T, Younan D, Cassuto NG, Bouret D, Hammoud I, Yazbeck C, Barak Y, Seshadri S, Bates M, Vince G, Jones DI, Ben Khalifa M, Montjean D, Menezo Y, Cohen-Bacrie P, Belloc S, De Mouzon J, Alvarez S, Aubriot FX, Olivennes F, Cohen M, Prisant N, Boudjema E, Magli MC, Crippa A, Baccetti B, Ferraretti AP, Gianaroli L, Singer T, Neri QV, Hu JC, Maggiulli R, Kollman Z, Rauch E, Schlegel PN, Rosenwaks Z, Palermo GD, Zorn B, Skrbinc B, Matos E, Golob B, Pfeifer M, Osredkar J, Sabanegh E, Sharma RK, Thiyagarajan A, Agarwal A, Robin G, Boitrelle F, Marcelli F, Marchetti C, Mitchell V, Dewailly D, Rigot JM, Rives N, Perdrix A, Travers A, Milazzo JP, Mousset-Simeon N, Mace B, Jakab A, Molnar Z, Benyo M, Levai I, Kassai Z, Golob B, Zorn B, Ihan A, Kopitar A, Kolbezen M, Vaamonde D, Da Silva-Grigoletto ME, Garcia-Manso JM, Vaamonde-Lemos R, Oehninger SC, Walis G, Monahan D, Neri QV, Ermolovich E, Rosenwaks Z, Palermo GD, Fadlon E, Abu Elhija A, Abu Elhija M, Lunenfeld E, Huleihel M, Costantini-Ferrando M, Maggiulli R, Neri QV, Hu JCY, Monahan D, Rosenwaks Z, Palermo GD, Alvarez JG, Gosalvez A, Velilla E, Lopez-Teijon M, Lopez-Fernandez C, Gosalvez J, Tempest HG, Sun F, Oliver-Bonet M, Ko E, Turek P, Martin RH, Zomeno-Abellan MT, Ramirez A, Gutierrez-Adan A, Martinez JC, Landeras J, Ballesta J, Aviles M, Lafuente R, Lopez G, Monqaut A, Brassesco M, Ganaiem M, Binder S, Abu Elhija M, Lunenfeld E, Meinhardt A, Huleihel M, Sousa L, Grangeia A, Carvalho F, Sousa M, Barros A, Sifer C, Sermondade N, Hafhouf E, Poncelet C, Benzacken B, Levy R, Wolf JP, Crisol L, Aspichueta F, Hernandez ML, Exposito A, Matorras R, Ruiz-Larrea MB, Ruiz-Sanz JI, Jallad S, Atig F, Ben Amor H, Saad ALI, Kerkeni A, Ajina M, Othmane ALI, Koscinski I, Ladureau L, Wittemer C, Viville S, Scarselli F, Casciani V, Lobascio M, Minasi MG, Rubino P, Colasante A, Arizzi L, Litwicka K, Iammarrone E, Ferrero S, Mencacci C, Franco G, Zavaglia D, Nagy ZP, Greco E, Ohgi S, Takahashi M, Kishi C, Suga K, Yanaihara A, Chamley LW, Wagner A, Shelling AN. Andrology (Male Fertility, Spermatogenesis). Hum Reprod 2010. [DOI: 10.1093/humrep/de.25.s1.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Höti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T, Liu M, Lupold SE, Rodriguez R. Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses. Cancer Gene Ther 2010; 17:585-97. [PMID: 20448671 DOI: 10.1038/cgt.2010.15] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Conditionally replicating adenoviruses (CRAds) represent a promising modality for the treatment of neoplastic diseases, including Prostate Cancer. Selectively replicating viruses can be generated by placing a tissue or cancer-specific promoter upstream of one or more of the viral genes required for replication (for example, E1A, E1B). We have previously reported multiple cellular processes that can attenuate viral replication, which in turn compromises viral oncolysis and tumor kill. In this study, we investigated the importance of the cyclin-dependent kinase inhibitor p21/Waf-1, on viral replication and tumor growth. To our knowledge, this is the first report describing the importance of p21/Waf-1shRNA on the induction of an androgen responsive element (ARE) based promoter driving the E1A gene. As a proof of concept, the study emphasizes the use of RNA interference technology to overcome promoter weaknesses for tissue-specific oncolytic viruses, as well as the cellular inhibitor pathways on viral life cycle. Using RNA interference against p21/Waf-1, we were able to show an increase in viral replication and viral oncolysis of prostate cancer cells. Similarly, CRAd viruses that carry p21/Waf-1 shRNA (Ad5-RV004.21) were able to prevent tumor outgrowth that resulted in a marked increase in the mean survival time of tumor-bearing mice compared with CRAd without p21/Waf-1 shRNA (Ad5-RV004). In studies combining Ad5-RV004.21 with Adriamycin, a suprar-additive effect was observed only in CRAds that harbor shRNA against p21/Waf-1. Taken together, these findings of enhanced viral replication in prostate cancer cells by using RNA interference against the cdk inhibitor p21/Waf-1 have significant implications in the development of prostate-specific CRAd therapies.
Collapse
Affiliation(s)
- N Höti
- Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287-2101, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Liu FC, Zhao JP, Hu BW, Zeng YF, Ribas J, Bu XH. One-dimensional metal-azido complex constructed by a double EO azido bridged trinuclear nickel(ii) unit: synthesis, structure and magnetic properties. Dalton Trans 2010; 39:1185-7. [DOI: 10.1039/b915616j] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
28
|
Jana A, Saha R, Ghosh A, Manna S, Ribas J, Ray Chaudhuri N, Mostafa G. Role of weak interactions in controlling the topology of coordination polymeric chains in [Pt(CN)4]2− bridged Cu(II) complexes: Syntheses, crystal structure and magnetic studies. Polyhedron 2009. [DOI: 10.1016/j.poly.2009.06.076] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Pasaro R, Ribas-Salgueiro JL, Matarredona ER, Sarmiento M, Ribas J. Systemic inhibition of the Na(+)/H (+) exchanger type 3 in intact rats activates brainstem respiratory regions. Adv Exp Med Biol 2009; 648:395-401. [PMID: 19536504 DOI: 10.1007/978-90-481-2259-2_45] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Selective inhibition of the Na(+)/H(+) exchanger type 3 (NHE3) increases the firing rate of brainstem ventrolateral CO(2)/H(+) sensitive neurons, resembling the responses evoked by hypercapnic stimuli. In anesthetized animals, NHE3 inhibition has also been shown to stimulate the central chemosensitive drive. We aimed to analyze the respiratory-related brainstem regions affected by NHE3 inhibition in anaesthetized spontaneously-breathing rats with intact peripheral afferents. For that, c-Fos immunopositive cells were counted along the brainstem in rats intravenously infused with the selective NHE3 inhibitor AVE1599. A rostral extension of the ventral respiratory column which includes the pre-Bötzinger complex was activated by the NHE3 inhibitor. In addition, the number of c-Fos positive cells resulted significantly increased in the most rostral extension of the retrotrapezoid nucleus/parapyramidal region. In the pons, the intravenous infusion of AVE1599 activated the lateral parabrachial and Kölliker-Fuse nuclei. Thus, selective NHE3 inhibition in anaesthetized rats activates the respiratory network and evokes a pattern of c-Fos expressing cells similar to that induced by hypercapnia.
Collapse
Affiliation(s)
- R Pasaro
- Department of Physiology and Zoology, University of Seville, Seville, Spain.
| | | | | | | | | |
Collapse
|
30
|
Liu FC, Zeng YF, Zhao JP, Hu BW, Hu X, Ribas J, Bu XH. Novel lanthanide–azido complexes: hydrothermal syntheses, structures and magnetic properties. Dalton Trans 2009:2074-6. [PMID: 19274282 DOI: 10.1039/b819955h] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Affiliation(s)
- Fu-Chen Liu
- Department of Chemistry, Nankai University, Tianjin, 300071, China
| | | | | | | | | | | | | |
Collapse
|
31
|
Martin M, Del Cacho E, Codina C, Tuset M, De Lazzari E, Mallolas J, Miró JM, Gatell J, Ribas J. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 2008; 24:1263-8. [PMID: 18834323 DOI: 10.1089/aid.2008.0141] [Citation(s) in RCA: 118] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The relationship between adherence, antiretroviral regimen, and viral load (VL) suppression was assessed through a 1 year prospective follow-up study among 1142 HIV-infected patient. Patients on antiretroviral therapy who attended to the pharmacy during a 6-month period were considered eligible. Those included in the final analysis were patients who had been taking the same antiretroviral therapy for > or =6 months since their inclusion. The cohort included patients taking first line therapy (n = 243) and antiretroviral-experienced patients (n = 899). Naive patients who were included had to have reached undetectable VL at enrollment. Antiretroviral-experienced patients with detectable VL determinations in the previous 6 months were excluded. Adherence was measured by means of announced pill counts and dispensation pharmacy records. Of patients, 58% were taking NNRTI, 31.4% boosted PI, and 10.6% unboosted PI-based regimens. Overall, the relative risk of virologic failure was 9.0 (95% CI 4.0-20.1) in patients with adherence 80-89.9%, 45.6 (95% CI 19.9-104.5) with adherence 70-79.9%, and 77.3 (95% CI 34.2-174.9) with adherence <70%, compared with adherence of > or =90%. The risk of virologic failure in patients with adherence <90% taking unboosted PI was 2.5 times higher than the group taking boosted PI (95% CI 1.2-5.3). There were no statistical differences in patients taking boosted PI and those who were taking NNRTI. Less than 95% of adherence is associated with high virologic success. For patients taking NNRTI- or boosted PI-based regimens with adherence rates of 80%, the failure rate is <10%. These data do not affect the goal of achieving the highest level of adherence possible.
Collapse
Affiliation(s)
- M. Martin
- Pharmacy Department, Hospital Clinic, 08036 Barcelona, Spain
| | - E. Del Cacho
- Pharmacy Department, Hospital Clinic, 08036 Barcelona, Spain
| | - C. Codina
- Pharmacy Department, Hospital Clinic, 08036 Barcelona, Spain
| | - M. Tuset
- Pharmacy Department, Hospital Clinic, 08036 Barcelona, Spain
| | - E. De Lazzari
- Epidemiology and Biostatistics Department, Hospital Clinic, 08036 Barcelona, Spain
| | - J. Mallolas
- Infectious Diseases Department, Hospital Clinic, 08036 Barcelona, Spain
| | - J.-M. Miró
- Infectious Diseases Department, Hospital Clinic, 08036 Barcelona, Spain
| | - J.M. Gatell
- Infectious Diseases Department, Hospital Clinic, 08036 Barcelona, Spain
| | - J. Ribas
- Pharmacy Department, Hospital Clinic, 08036 Barcelona, Spain
| |
Collapse
|
32
|
Ghosh AK, Ghoshal D, Zangrando E, Ribas J, Chaudhuri NR. Syntheses, Crystal Structures, and Magnetic Properties of Metal−Organic Hybrid Materials of Cu(II): Effect of a Long Chain Dicarboxylate Backbone, and Counteranion in Their Structural Diversity. Inorg Chem 2007; 46:3057-71. [PMID: 17373784 DOI: 10.1021/ic061720v] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Eight new metal-organic hybrid materials of Cu(II) have been synthesized by using flexible glutarate/adipate as a bridging ligand, 2,2'-bipyridine/1,10-phenanthroline as a chelating ligand, and BF4-/ClO4-/Cl- as a counteranion. These materials are characterized by single-crystal X-ray diffraction analyses and variable temperature magnetic measurements. Out of them, complexes 1, 3, 5, and 8 crystallize in the triclinic system with space group P. Complexes 2, 4, 6, and 7 crystallize in the monoclinic system with space group P21/n (2, 4), P21/c (6), and C2 (7). The structural analysis reveals that bridging glutarate gives rise to dinuclear and tetranuclear species, whereas the adipate dianion leads to octanuclear, one-dimensional and two-dimensional polymeric complexes, although they have been prepared under similar conditions. Supramolecular architectures of higher dimensionality have been achieved through H-bonding and pi-pi interaction. In all the complexes, the bridging and/or counteranions as well as chelating ligand have a vital role in directing the solid-state structure. A variable temperature (2-300 K) magnetic susceptibility study discloses the antiferromagnetic coupling for all of the complexes.
Collapse
Affiliation(s)
- A K Ghosh
- Department of Inorganic Chemistry, Indian Association for the Cultivation of Science, Kolkata, India
| | | | | | | | | |
Collapse
|
33
|
Bhuina P, Ray U, Mostafa G, Ribas J, Sinha C. One-dimensional azido bridge [1-ethyl-2-(phenylazo)imidazole]manganese(II): Structure of low bridge angle system and magnetism. Inorganica Chim Acta 2006. [DOI: 10.1016/j.ica.2006.07.042] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
34
|
Ribas J, Bettayeb K, Ferandin Y, Knockaert M, Garrofé-Ochoa X, Totzke F, Schächtele C, Mester J, Polychronopoulos P, Magiatis P, Skaltsounis AL, Boix J, Meijer L. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death. Oncogene 2006; 25:6304-18. [PMID: 16702956 DOI: 10.1038/sj.onc.1209648] [Citation(s) in RCA: 85] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Indirubin, an isomer of indigo, is a reported inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase-3 (GSK-3) as well as an agonist of the aryl hydrocarbon receptor (AhR). Indirubin is the active ingredient of a traditional Chinese medicinal recipe used against chronic myelocytic leukemia. Numerous indirubin analogs have been synthesized to optimize this promising kinase inhibitor scaffold. We report here on the cellular effects of 7-bromoindirubin-3'-oxime (7BIO). In contrast to its 5-bromo- and 6-bromo- isomers, and to indirubin-3'-oxime, 7BIO has only a marginal inhibitory activity towards CDKs and GSK-3. Unexpectedly, 7BIO triggers a rapid cell death process distinct from apoptosis. 7-Bromoindirubin-3'-oxime induces the appearance of large pycnotic nuclei, without classical features of apoptosis such as chromatin condensation and nuclear fragmentation. 7-Bromoindirubin-3'-oxime-induced cell death is not accompanied by cytochrome c release neither by any measurable effector caspase activation. Furthermore, the death process is not altered either by the presence of Q-VD-OPh, a broad-spectrum caspase inhibitor, or the overexpression of Bcl-2 and Bcl-XL proteins. Neither AhR nor p53 is required during 7BIO-induced cell death. Thus, in contrast to previously described indirubins, 7BIO triggers the activation of non-apoptotic cell death, possibly through necroptosis or autophagy. Although their molecular targets remain to be identified, 7-substituted indirubins may constitute a new class of potential antitumor compounds that would retain their activity in cells refractory to apoptosis.
Collapse
Affiliation(s)
- J Ribas
- CNRS, Cell Cycle Group and UPS2682, Station Biologique, Bretagne, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
López Alonso M, Moya MJ, Cabo JA, Ribas J, Macías MC, Silny J, Sifrim D. [Acid and non-acid gastro-esophageal reflux in newborns. Preliminar results using intraluminal impedance]. Cir Pediatr 2005; 18:121-6. [PMID: 16209372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
Preterm infants present often Gastroesophageal refluxes (GER). Esophageal pH monitoring to reflux detection is of limited use in this infants because their gastric pH is normally higher than 4 for 90% of the time. Other methods such as the Intraluminal Impedance Technique (MII) technique and the use of micromanometric catheters try to palliate the difficulties for measuring GER by pH monitoring. The aim of this study, in a first step, was to obtain the normal Intraluminal Impedance values on control children and, in a second step, to study the relationship between GER and cardiorespiratory episodes using simultaneous recording of the end-tidal fraction of expired CO2, 02 saturation by pulse-oximetry, respiratory frequency, esophageal impedance and manometry, gastro-esophageal pHmetry, and electrocardiography in selected patients. Data from simultaneous pH and Intraluminal Impedance during 24 hours in 7 control preterms showed 89 acid refluxes, 192 non-acid refluxes, 79.36% of all refluxes reached the proximal esophagus. Therefore the impedance is an innocuous method which opens new horizons in the study of such a common illness as the GER in the preterm infants.
Collapse
Affiliation(s)
- M López Alonso
- Dpto. Cirugía Pediátrica. Fundación Reina Mercedes. HUI Virgen del Rocío, Sevilla.
| | | | | | | | | | | | | |
Collapse
|
36
|
Ghosh AK, Ghoshal D, Zangrando E, Ribas J, Ray Chaudhuri N. Rare Azido-Bridged Manganese(II) Systems: Syntheses, Crystal Structures, and Magnetic Properties. Inorg Chem 2005; 44:1786-93. [PMID: 15762705 DOI: 10.1021/ic048466w] [Citation(s) in RCA: 98] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Two new polymeric azido-bridged manganese complexes of formulas [Mn(N3)2 (bpee)]n (1) and {[Mn(N3)(dpyo)Cl(H2O)2](H2O)}n (2) [bpee, trans-1,2-bis(4-pyridyl)ethylene; dpyo, 4,4'-dipyridyl N,N'-dioxide] have been synthesized and characterized by single-crystal X-ray diffraction analysis and low-temperature magnetic study. Both the complexes 1 and 2 crystallize in the triclinic system, space group P1, with a = 8.877(3) A, b = 11.036(3) A, c = 11.584(4) A, alpha = 72.62(2) degrees, beta = 71.06(2) degrees, gamma = 87.98(3) degrees, and Z = 1 and a = 7.060(3) A, b = 10.345(3) A, c = 11.697(4) A, alpha = 106.86(2) degrees, beta = 113.33(2) degrees, gamma = 96.39(3) degrees, and Z = 2, respectively. Complex 1 exhibits a 2D structure of [-Mn(N3)2-]n chains, connected by bpee ligands, whose pyridine rings undergo pi-pi and C-H...pi interactions. This facilitates the rare arrangement of doubly bridged azide ligands with one end-on and two end-to-end (EO-EE-EE) sequence. Complex 2 is a neutral 1D polymer built up by [Mn(N3)(dpyo)Cl(H2O)2] units and lattice water molecules. The metals are connected by single EE azide ligands, which are arranged in a cis position to the Mn(II) center. The 1D zipped chains are linked by H-bonds involving lattice water molecules and show pi-pi stacking of dpyo pyridine rings to form a supramolecular 2D layered structure. The magnetic studies were performed in 2-300 K temperature range, and the data were fitted by considering an alternating chain of exchange interactions with S = 5/2 (considered as classical spin) with the spin Hamiltonians H = -Ji sigma(S(3i)S(3i+1) + S(3i+1)S(3i+2)) - J2 sigmaS(3i-1)S(3i) and H = -Ji sigmaS(2i)S(2i+1) - J2 sigmaS(2i+1)S(2i+2) for complexes 1 and 2, respectively. Complex 2 exhibits small antiferromagnetic coupling between the metal centers, whereas 1 exhibits a new case of topological ferromagnetism, which is very unusual.
Collapse
Affiliation(s)
- A K Ghosh
- Department of Inorganic Chemistry, Indian Association for the Cultivation of Science, Kolkata-700 032, India
| | | | | | | | | |
Collapse
|
37
|
Rodríguez E, Beltrán E, Ribas J, Torres M. Apendicitis aguda como inicio de una tuberculosis generalizada. Gastroenterología y Hepatología 2004; 27:43-4. [PMID: 14718112 DOI: 10.1016/s0210-5705(03)70447-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
38
|
Muntada E, Masso´ J, Del Pozo A, Creus N, Pe´rez-Cebria´n M, Miana M, Lo´pez E, Ribas J. Compatibility of drugs with total nutrient admixtures (TNA) containing different lipid emulsions. Clin Nutr 2003. [DOI: 10.1016/s0261-5614(03)80382-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
39
|
Abstract
The ventral surface of the caudal ventrolateral medulla (cVLM) has been shown to generate intense respiratory responses after surface acid-base stimulation. With respect to their chemosensitive characteristics, cVLM neurons have been less studied than other rostral-most regions of the brainstem. The purpose of these experiments was to determine the bioelectric responses of cVLM neurons to acidic stimuli and to determine their chemosensitive properties. Using extracellular and microiontophoretic techniques, we recorded electrical activities from 117 neurons in an area close to the ventral surface of the cVLM in anaesthetised rats. All neurons were tested for their sensitivity to H+. The fluorescent probe BCECF was used to measure extracellular pH changes produced by the microiontophoretic injection of H+ in brainstem slices. This procedure provided an estimation of the local changes in pH produced by microiontophoretic H+ application in the anaesthetised rat. Neurons coupled to the respiratory cycle, R (n = 51), were not responsive to direct stimulation with H+. Sixty-six neurons that did respond to H+ stimulation were uncoupled from respiration, and identified as NR neurons. These neurons presented distinct ranges of H+ sensitivity. The neuronal sensitivity to H+ was mainly assessed by the slope of the stimulus-response curve, where the steeper the slope, the higher the H+ sensitivity. On this basis, NR neurons were classed as being either weakly or highly sensitive to H+. NR neurons with a high H+ sensitivity (n = 12) showed an average value of 34.17 +/- 7.44 spikes s-1 (100 nC)-1 (mean +/- S.D.) for maximal slope and an EC50 of 126.76 +/- 33 nC. Suprathreshold H+ stimulation of highly sensitive NR neurons elicited bursting pattern responses coupled to the respiratory cycle. The bursting responses, which were synchronised with the inspiratory phase and the early expiratory phase of the respiratory cycle, lasted for several seconds before returning to the steady state firing pattern characteristic of the pre-stimulus condition. These NR neurons, which possess the capacity to detect distinct H+ concentrations in the extracellular microenvironment, are excellent candidates to serve in a chemoreceptor capacity in the caudal medulla.
Collapse
|
40
|
Cooke J, Kubin M, Morris T, Ribas J, Krämer I, Kämmerer W, Fornaini R, Ballet AC, Sagnier PP. Intravenous and oral antibiotics in respiratory tract infection: an international observational study of hospital practice. Pharm World Sci 2002; 24:247-55. [PMID: 12512158 DOI: 10.1023/a:1021522226178] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND Hospitalised patients with respiratory tract infections (RTI) frequently receive intravenous (i.v.) antibiotics followed by a short course of oral treatment. OBJECTIVES To observe antibiotic use in hospitals in Germany, Spain, France, Italy and the UK and the reasons for choosing the i.v. route and switching to oral treatment. METHODS Research pharmacists sought the opinions of physicians and senior nurses in the completion of a semi-structured questionnaire on the treatment of RTI with i.v. antibiotics. Questions focussed on antimicrobials of choice, reasons for choosing i.v., reasons for changing to oral administration, and duration of treatment. RESULTS This study recruited 796 patients with RTI, usually pneumonia. Prescribing patterns varied widely between the five hospitals. Accepted clinical criteria were only commonly cited in Germany, Spain and the UK as reasons for choosing the i.v. route at the beginning of the study. These were more commonly cited at the time of switch, although other criteria such as improved condition, were other significant reasons. The mean duration of i.v. treatment ranged from 4 days in the UK to 10 days in Italy, where most patients received the full course of treatment by the i.v. route. Unlike the other hospitals studied, the few patients in Italy who were switched to another form of treatment were as likely to receive intramuscular as oral administration (13% and 11%, respectively). CONCLUSIONS The practice of and reasons for prescribing i.v. antibiotics varied in the hospitals studied. Objective clinical criteria were inconsistently cited as reasons for administering i.v. antibiotics and in general these reasons were unrelated to those given for the switch from i.v. to oral administration. In order for guidelines for switching from i.v. to oral antimicrobials to be routinely employed, explicit physiological criteria need to be recorded in a routine fashion. Closer co-operation between pharmacists and physicians may help in developing and implementing guidelines at a local level.
Collapse
Affiliation(s)
- J Cooke
- South Manchester University Hospitals NHS Trust, Withington Hospital, Manchester, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Creus N, Mateu J, Massó J, Codina C, Ribas J. Toxicity to topical dimethyl sulfoxide (DMSO) when used as an extravasation antidote. Pharm World Sci 2002; 24:175-6. [PMID: 12426960 DOI: 10.1023/a:1020528203296] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
DMSO is a dipolar, aprotic, hygroscopic solvent for which a large number of pharmacologic properties have been claimed. Topical DMSO is considered an effective and safe antidote to be used with topical cooling after extravasations of vesicant drugs. A case of toxicity after its use as an antidote is described. Furthermore, the increasing importance of DMSO pharmacology, as its use in haematologic patients is spreading, is reviewed.
Collapse
Affiliation(s)
- N Creus
- Pharmacy Department, Hospital Clinic of Barcelona, c/Villarroel 170, 08036 Barcelona, Spain.
| | | | | | | | | |
Collapse
|
42
|
Sánchez D, Armengol JA, Ribas J. The Study of Passive Membrane Properties and Morphology Reveals Neuronal Differences Along the Sagittal Axis of the Ventral Periaqueductal Grey Matter. Eur J Neurosci 2002; 2:1135-1143. [PMID: 12106074 DOI: 10.1111/j.1460-9568.1990.tb00025.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The membrane properties of the neurons located in the ventral part of the periaqueductal grey (PAG) of the guinea-pig were studied using an in vitro slice preparation. Cells had low values of resting membrane potential (-53.3 +/- 1.3 mV, mean +/- standard error), high input resistance (195. +/- 16.2 M ohm) and moderate values of membrane time constant (12.6 +/- 0.7 ms). The last two parameters changed as recordings were made along the sagittal axis, higher values corresponding to the more rostral cells. Three main neuronal types-fusiform, triangular and stellate-were found in the ventral PAG using intracellular injection of Lucifer yellow. A study of the cell number and cell density was carried out in coronal and sagittal sections of the ventral PAG. This analysis showed a clear gradient of size in this region arising from the gradual disappearance of large (17 to 40 microm) neurons in the caudorostral direction. The neuronal density also increased in this direction. Therefore, some electrotonic and morphological parameters differ along the sagittal axis. These findings suggest a larger neuronal heterogeneity of the caudal part of the PAG, and might contribute to a functional segregation of this region.
Collapse
Affiliation(s)
- D. Sánchez
- Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, E-41009, Sevilla, Spain
| | | | | |
Collapse
|
43
|
Casabo J, Flor T, Teixidor F, Ribas J. Solid-state kinetic parameters for the deaquation-anation of the double complex salts pentaammineaquacobalt(3+) acidopentacyanocobaltate (acido = CN, Cl, Br, I, NO2, N3) and the preparation of dinuclear derivatives with .mu.-cyano bridges. Inorg Chem 2002. [DOI: 10.1021/ic00238a015] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
44
|
Ribas J, Jiménez MJ, Barberà JA, Roca J, Gomar C, Canalís E, Rodriguez-Roisin R. Gas exchange and pulmonary hemodynamics during lung resection in patients at increased risk: relationship with preoperative exercise testing. Chest 2001; 120:852-9. [PMID: 11555520 DOI: 10.1378/chest.120.3.852] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
STUDY OBJECTIVES To evaluate the intraoperative evolution of patients with COPD during lung resection and to test whether exercise testing could be helpful in the prediction of the intraoperative course. DESIGN Prospective study. SETTING University teaching hospital. PATIENTS Forty patients (mean [+/- SD] age, 65 +/- 9 years) with COPD (ie, FEV(1), 55 +/- 11% of predicted) and resectable lung neoplasms. INTERVENTIONS Preoperatively, pulmonary function testing, quantitative lung perfusion scanning, and exercise performance testing were administered. Intraoperatively, pulmonary, hemodynamic, and blood gas measurements were performed at five stages, including periods of two-lung ventilation (TLV) and periods of one-lung ventilation (OLV). RESULTS During OLV, compared with TLV, the PaO(2)/fraction of inspired oxygen (FIO(2)) ratio decreased from 458 +/- 120 to 248 +/- 131 mm Hg (p < 0.05), whereas pulmonary artery pressure (PAP) increased from 18 +/- 5 to 23 +/- 5 mm Hg (p < 0.05). Cardiac output (t) also increased from 4.0 +/- 1.2 to 5.1 +/- 1.9 L/min (p < 0.05), yielding to a higher mixed venous PO(2). Both PaO(2) and t during OLV were significantly lower in patients who had undergone right thoracotomies compared with those who had undergone left thoracotomies. The PaO(2)/FIO(2) ratio during OLV correlated with the PaO(2) during exercise (r = 0.39; p = 0.01) and with the perfusion of the non-neoplastic lung (r = 0.44; p = 0.005). CONCLUSIONS In COPD patients, OLV leads to a significant derangement of gas exchange, which is more pronounced in right thoracotomies. Preoperative measurement of PaO(2) during exercise and the distribution of perfusion by lung scan might be useful to identify those patients who are at the greatest risk of abnormal gas exchange during lung resections.
Collapse
Affiliation(s)
- J Ribas
- Serveis de Pneumologia i Allèrgia Respiratòria, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
45
|
Tercero J, Diaz C, El Fallah MS, Ribas J, Solans X, Maestro MA, Mahía J. Synthesis, characterization, and magnetic properties of self-assembled compounds based on discrete homotrinuclear complexes of Cu(II). Inorg Chem 2001; 40:3077-83. [PMID: 11399175 DOI: 10.1021/ic001028e] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Three new supramolecular entities of Cu(II) were synthesized and characterized: [(Cu(H(2)O)(tmen))(2)(mu-Cu(H(2)O)(opba))](2)[(ClO(4))(2)](2).2H(2)O (1), [(Cu(H(2)O)(tmen))(2) (mu-Cu(H(2)O) (Me(2)pba))](2)[(ClO(4))(2)](2) (2), and [(Cu(H(2)O)(tmen))(Cu(tmen))(mu-Cu(OHpba))](n)() ((ClO(4))(2))(n)().nH(2)O (3), where opba = o-phenylenbis(oxamato), Me(2)pba = 2,2-dimethyl-1,3-propylenbis(oxamato), OHpba = 2-hydroxy-1,3-propylenbis(oxamato), and tmen = N,N,N'N'-tetramethylethylenediamine. The crystal structures of 1, 2, and 3 were solved. Complex 1 crystallizes in the monoclinic system, space group C2/c with a = 20.572(4) A, b = 17.279(6) A, c = 22.023(19) A, beta = 103.13(4) degrees, and Z = 8. Complex 2 crystallizes in the monoclinic system, space group P2(1)/c, with a = 16.7555(7) A, b = 13.5173(5) A, c = 17.1240(7) A, beta = 104.9840(10) degrees, and Z = 4. Complex 3 crystallizes in the orthorhombic system, space group Pca2(1) with a = 21.2859(4) A, b = 12.8286(10) A, c = 12.6456(2) A, and Z = 4. The three complexes are very similar in structure: a trinuclear Cu(II) complex with the two terminal Cu(II) ions blocked by N,N,N',N'-tetramethylethylenediamine, but with a different environment in the Cu(II) central ion. In the case of complex 1, two of these trinuclear entities are packed with a short distance between the central Cu(II) ions of two separate entities forming a hexanuclear-type compound. In the case of 2, two of these trinuclear entities are linked by a hydrogen bond between a water molecule of one terminal Cu(II) and one oxygen atom of the oxamato ligand of the neighboring entity, also forming a hexanuclear complex. In the case of complex 3, the intermolecular linkages give a one-dimensional system where the OH groups of the OHpba entities are linked to the terminal Cu(II) of the neighboring entities. The magnetic properties of the three complexes were studied by susceptibility measurements vs temperature. For complex 1, an intramolecular J value of -312.1 cm(-)(1) and a contact dipolar interaction of -0.44K were found. For complex 2 and 3 the fit was made by the irreducible tensor operator formalism (ITO). The values obtained were as follows: J(1) = -333.9 cm(-)(1) and J(2) = 0.67 cm(-)(1) for 2 and J(1) = -335.9 cm(-)(1) and J(2) = 3.5 cm(-)(1) for 3.
Collapse
Affiliation(s)
- J Tercero
- Departament de Química Inorgànica, Universitat de Barcelona, Diagonal 647, 08028 Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
46
|
Echazarreta AL, Gómez FP, Ribas J, Sala E, Barberà JA, Roca J, Rodriguez-Roisin R. Pulmonary gas exchange responses to histamine and methacholine challenges in mild asthma. Eur Respir J 2001; 17:609-14. [PMID: 11401053 DOI: 10.1183/09031936.01.17406090] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Histamine (HIST) produces greater changes in bronchial and pulmonary vasculature, and so may produce more gas exchange abnormalities, than methacholine (MTH) after inhalational challenge. The goals of this study were to compare the effects of HIST and MTH challenge on pulmonary gas exchange in patients with mild asthma at an equivalent degree of bronchoconstriction. Eleven patients were studied (mean+/-SEM age, 22+/-1 yr; forced expiratory volume in one second (FEV1), 91+/-5% pred) using a randomized, double-blind cross-over design. Respiratory system resistance (Rrs), arterial blood gases, and ventilation-perfusion distributions were measured before and after HIST/MTH challenges when cumulative doses caused a 30% fall in FEV1. Compared with baseline, HIST and MTH provoked similar moderate to severe increases in Rrs (p<0.005 each), and mild to moderate decreases in arterial oxygen tension (Pa,O2) due to ventilation-perfusion abnormalities (dispersion of pulmonary blood flow -log SDQ-, 0.40+/-0.03-0.71+/-0.08 and 0.47+/-0.04-0.89+/-0.06; normal values <0.60-0.65), respectively, similar to those shown in mild to moderate acute asthma, without differences between them. For the same degree of airflow obstruction, both histamine and methacholine bronchoprovocations induce, in patients with mild asthma, very similar disturbances in ventilation-perfusion distribution and respiratory system resistance, suggesting similar mechanisms of airway narrowing.
Collapse
Affiliation(s)
- A L Echazarreta
- Dept de Medicina, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Spain
| | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
OBJECTIVE Withdrawal of a drug from the market for safety reasons is a serious and sometimes complex decision. The scientific evidence supporting drug withdrawals in the past years is critically appraised. METHODS With data provided by the Spanish Medicines Agency, all drugs withdrawn from the Spanish market for safety reasons from January 1990 to December 1999 were identified. The adverse drug reactions (ADRs) were classified by the year of withdrawal, by the organ/system affected and by the alleged type of reaction (Rawlins and Thompson classification). A systematic review of the literature was performed. RESULTS A total of 22 drugs were withdrawn from the market due to safety reasons. In 18 of 22 cases (82%), the evidence supporting the drug withdrawal came from individual case reports, cases series or the combination of data provided by randomised clinical trials and case reports. Hepatic (eight cases) and cardiac (five cases) reactions accounted for 59% (13 of 22) of the total withdrawals. In 10 of 22 (45%) cases, drug withdrawal was clearly due to type-B reactions. Only four withdrawals were based on evidence from observational studies including a comparison group. CONCLUSION Case reports are the main source of information used to withdraw a drug from the market for safety reasons. It is necessary to improve the quality of evidence supporting the withdrawal process of drugs linked to unexpected and severe ADRs. The use of large databases to perform cohort or nested case-control analyses is the most efficient and reliable method to study type-A class effect ADRs. The implementation of such databases in different countries could increase the quality of the information on ADRs by allowing researchers to conduct efficiently these type of studies.
Collapse
Affiliation(s)
- J A Arnaiz
- Clinical Pharmacology, UASP, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain.
| | | | | | | | | | | |
Collapse
|
48
|
Monfort M, Resino I, El Fallah MS, Ribas J, Solans X, Font-Bardia M, Stoeckli-Evans H. Synthesis, structure, and magnetic properties of three new one-dimensional nickel(II) complexes: new magnetic model for the first one-dimensional S = 1 complex with alternating ferro-ferromagnetic coupling. Chemistry 2001; 7:280-7. [PMID: 11205021 DOI: 10.1002/1521-3765(20010105)7:1<280::aid-chem280>3.0.co;2-1] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Three new one-dimensional nickel(II) complexes with the formulas trans-[Ni(N-Eten)2(mu1.3-N3)]n(ClO4)n (1), trans-[Ni(N-Eten)2(mu1.3-N3)]n(PF6)n (2), and cis-[Ni(N-Eten)(mu1.1-N3)2]n (3) (N-Eten = N-Ethylethylenediamine) were synthesized and characterized. Complex 1 has the P2(1)/c space group and consists of a structurally and magnetically alternating one-dimensional antiferromagnetic system with end-to-end azido bridges. Compound 2 has the P1 space group and has alternate units in its structure but consists of a magnetically uniform one-dimensional antiferromagnetic system with end-to-end azido bridges. Complex 3 has the I2/a space group and may be described as a structurally and magnetically alternating one-dimensional ferromagnetic system with double azido bridged ligands in an end-on coordination mode. The chi(M)T versus T plots for compound 3 suggest an intramolecular ferromagnetic interaction between adjacent NiII ions and metamagnetism at low temperature (below 10 K). The magnetization measurements versus applied field confirm this metamagnetic ordering. In order to describe the magnetic data of this compound we developed a general formula for the magnetic susceptibility of the isotropic ferro-ferromagnetic S = 1 Heisenberg chain in terms of the alternation parameter alpha (= J2/J1); this assumed a variation of chi(M)T versus the length N.
Collapse
Affiliation(s)
- M Monfort
- Departament de Química Inorgànica, Universitat de Barcelona, Spain.
| | | | | | | | | | | | | |
Collapse
|
49
|
Lo SC, Levin L, Ribas J, Chung R, Wang RY, Wear D, Shih JW. Lack of serological evidence for Mycoplasma fermentans infection in army Gulf War veterans: a large scale case-control study. Epidemiol Infect 2000; 125:609-16. [PMID: 11218212 PMCID: PMC2869645 DOI: 10.1017/s0950268800004891] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Mycoplasma firmentans is suspected in the development of 'Gulf War illness' in veterans of Operation Desert Storm. We conducted a matched case-control study for the prevalence of M. firmentans-specific antibodies before and after the operation, as well as seroconversion rates in veterans with and without complaints of 'Gulf War illness'. Cases consisted of Gulf War veterans, who complained of various illnesses and were enrolled in the second phase of the health evaluation by the Army Comprehensive Clinical Examination Program (CCEP). Controls were selected from Gulf War veterans who did not participate in the registry and did not request a health evaluation by the CCEP. Before operation deployment, 34 out of 718 of the cases (48%) and 116 out of 2233 of the controls (5.2%) tested positive for M. fermentans-specific antibodies. There was no difference in rates of seroconversion between cases and controls (1.1 vs. 1.2%) to M. fermentans during Operation Desert Storm. Thus, there is no serological evidence that suggests infectionby M. fermentans is associated with development of 'Gulf War illness'.
Collapse
Affiliation(s)
- S C Lo
- Department of Infectious and Parasitic Diseases Pathology, Armed Forces Institute of Pathology, Washington, DC 20306, USA
| | | | | | | | | | | | | |
Collapse
|
50
|
Bertrán MJ, Trilla A, Codina C, Carné X, Ribas J, Asenjo MA. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community]. Enferm Infecc Microbiol Clin 2000; 18:445-51. [PMID: 11149168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
BACKGROUND Cost of treatment of community-acquired infections in Spain is an important factor in overall health expenditures. The aim of this study was to assess the direct health costs related with the treatment of patients with community-acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB) due to infection, using different antibiotic options, and to identify main cost drivers. METHODS A basic decision analysis model was developed, including probabilities estimation derived from the literature review, supplemented when needed by the opinion of a panel of 8 Spanish physicians (Delphi technique). Four groups of antibiotics were included (macrolides, beta-lactam, fluoroquinolones and cephalosporins) in two different groups: patients with CAP without hospital admission criteria and patients with AECB due to respiratory infection. The analytic horizon and the perspective used were those of the Spanish National Health Service. Direct cost were assessed (drugs, outpatient visits, hospital admissions, diagnostic tests). Indirect cost were not included in the model. Final costs uses as main outcome measure the average cost per patient treated. All results were calculated following a fold-back technique. Sensitivity analysis were included allowing for variations in several clinically relevant parameters. RESULTS 1. Patients with CAP: Hospital admissions, directly related to the effectiveness rate of initial empirical antibiotic therapy, were the main cost driver (50%-70%). Acquisition costs of initial antibiotic therapy only account for 2%-13% of total costs. 2. Patients with AECB: Outpatient visits are the main cost driver for these group of patients (49% of total costs). Hospital admission costs are also an important cost driver (40%-51% of total costs). Acquisition costs of initial antibiotic therapy account for 4%-28% of total costs. Clinical effectiveness of first antibiotic option is the main variable regarding the cost-effectiveness rate. CONCLUSION The model here presented showed that acquisition costs of first empirical antibiotic therapy are only a small proportion of total costs related with the management of community acquired lower respiratory tract infections in Spain. The clinical effectiveness rate of the first antibiotic used is the main variable which determines the final average cost per patient cured. For patients with lower respiratory tract infections the therapeutic option with a better cost-effectiveness ratio must be chosen, in order to minimize the risk of therapeutic failure after first line therapy, and should not be selected only by its lower acquisition costs.
Collapse
Affiliation(s)
- M J Bertrán
- Epidemiología Hospitalaria-Centro de Epidemiología, Evaluación, Soporte y Prevención (CEASP)
| | | | | | | | | | | |
Collapse
|